Linked Life Data

19235589

Source:http://linkedlifedata.com/resource/pubmed/id/19235589

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-2-24
pubmed:abstractText
Vascular endothelial growth factor (VEGF) is the key molecule mediating tumor growth and malignant ascites formation. We recently reported that, in an end stage OVCAR-3 xenograft model, albendazole (ABZ) suppresses ascites formation, but not tumor growth. Hence, in the present study, we assessed the effect of ABZ on in vitro OVCAR-3 cell proliferation plus in vivo tumor growth, however, initiating ABZ treatment at mid stage (3 weeks post cell inoculation) rather than end stage disease. Here, ABZ treatment led to potent inhibition of cell proliferation, VEGF suppression, complete inhibition of ascites formation and most strikingly arrest of tumor growth.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1532-4192
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
171-7
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole.
pubmed:affiliation
Cancer Research laboratories, University of New South Wales, Department of Surgery, St George Hospital (SESIAHS), Sydney, Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't